Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06685211 · ClinicalTrials.gov registry record · NA

Electrical Stimulation for Vision Neuroenhancement in Glaucoma

A NA study of Glaucoma and Glaucoma Open-Angle, sponsored by Stanford University.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06685211 is a NA study of Glaucoma and Glaucoma Open-Angle that is actively recruiting participants, run by Stanford University. The registered enrollment target is 30 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06685211, a NA study of Glaucoma and Glaucoma Open-Angle, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to evaluate the efficacy, transorbital alternating current stimulation (rtACS) using the EYETRONIC for the treatment in patients with glaucoma.

Interventions

  • DEVICE Eyetronic rtACS
  • DEVICE Sham rtACS

Study Locations (1)

California

  • Byers Eye Institute at Stanford University - Palo Alto

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-07-14
Est. Completion 2027-12-31
Phase NA

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT06685211

The ClinicalTrials.gov registry entry for NCT06685211 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (97% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Eyetronic rtACS is the first listed.

NCT06685211 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06685211 about?

NCT06685211 is a clinical study titled "Electrical Stimulation for Vision Neuroenhancement in Glaucoma". The purpose of the study is to evaluate the efficacy, transorbital alternating current stimulation (rtACS) using the EYETRONIC for the treatment in patients with glaucoma.

What is the current status of trial NCT06685211?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-07-14. Estimated completion is 2027-12-31.

What conditions does trial NCT06685211 study?

This clinical trial studies the following conditions: Glaucoma, Glaucoma Open-Angle.

What interventions are being tested in trial NCT06685211?

The interventions under investigation include: Eyetronic rtACS (DEVICE), Sham rtACS (DEVICE).

Who is sponsoring clinical trial NCT06685211?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06685211 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.